The study, consisting of over 1.4 billion prescriptions, found that a number of prescription drugs were highly associated with longer life- and health-span in long-live populations. Here, we present a unique investment opportunity. We seek to validate these observations through a series of carefully conducted wet lab experiments. If successful, this work could result in the repurposing of several FDA-approved therapeutics for the purpose of extending human lifespan, at a lower cost and over faster timelines than conceivably possible with de novo drug discovery. This unique investment opportunity allows savvy longevity investors the chance to own a share of the potential intellectual property generated from these studies, and in turn, a potential share in the future of life extension. Aims, Hypothesis & Results The global elderly population is projected to substantially increase throughout the 21st century. By the year 2100 a fifth of the total world population will be aged 65 or older, posing a serious socioeconomic challenge to societies world-wide. Interventions that ensure healthy aging are therefore of critical importance. Timeline The Scheibye-Knudsen Lab will test the identified drugs' ability to attenuate features of aging in a controlled laboratory setting. Here, the molecules will be tested in human cells and in the animal model drosophila melanogaster (fruit flies). Fruit flies are used extensively in biomedical research and particular aging research as they have a short lifespan of about 60 days. Additionally, the drugs will be tested in human cells to rapidly understand how the molecules affect human cellular aging.